Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering Corp's Chief Scientific Officer Brett Matthew Hall reported an open-market purchase of Class A Common Stock. On June 15, 2026, he bought 6,035 shares at a weighted average price of $4.15 per share. Following this transaction, he directly owns 382,531 shares of Immuneering Corp stock. The filing notes the trade was executed through a broker-dealer in multiple transactions at prices ranging from $4.146 to $4.15 per share, with the reported price representing the weighted average.
Immuneering Corporation is appointing Andrew Gengos as Chief Financial Officer, Treasurer and principal financial officer, effective when he starts work, expected on or before July 16, 2026. Current Senior Vice President Finance and Chief Accounting Officer Mallory Morales will remain the company’s principal accounting officer.
Gengos will receive an annual base salary of $530,000 and be eligible for a target annual bonus equal to 40% of base salary, based on Board-set objectives. As a material inducement to join, he is expected to receive an option to purchase 650,000 shares of common stock under the 2025 Employment Inducement Award Plan, contingent on his start date.
If terminated without cause or he resigns for good reason, he is eligible for 12 months of base salary continuation, any earned prior-year bonus, and up to 12 months of subsidized COBRA. After a qualifying change in control, he may instead receive similar salary and COBRA benefits, an additional payment equal to 1.0x his target bonus, and accelerated vesting of specified equity awards.
Immuneering Corp director Thomas J. Schall received a grant of stock options covering 33,350 shares of Class A common stock at an exercise price of $4.12 per share. The options vest in equal monthly installments over one year starting on July 11, 2026.
The award will be fully vested by June 11, 2027 or on the date of the 2027 annual meeting of stockholders, whichever occurs first. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Immuneering Corp director Diana Hausman received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and were awarded as compensation, not purchased in the market.
The option grant vests in equal monthly installments over one year starting on July 11, 2026, and will be fully vested by June 11, 2027 or the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, she holds options for 33,350 shares directly.
Immuneering Corp director Robert J. Carpenter received a grant of stock options for 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever occurs first. Following this grant, he holds 33,350 stock options directly.
Immuneering Corp director Laurie Keating received a grant of 33,350 stock options. These options allow her to buy Class A common stock at an exercise price of $4.12 per share and are held directly.
The options vest in equal monthly installments over one year starting on July 11, 2026. They will be fully vested and exercisable on June 11, 2027, or on the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, Keating holds 33,350 stock options in total.
Immuneering Corp director Peter Feinberg received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and expire on June 11, 2036. They vest in equal monthly installments over one year starting July 11, 2026, becoming fully vested by June 11, 2027 or the 2027 annual stockholder meeting, whichever comes first. Following this grant, Feinberg holds 33,350 stock options directly.
Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where stockholders voted on director elections and the auditor appointment. A total of 44,495,059 Class A common shares were present in person or by proxy, representing approximately 68.8 percent of shares outstanding as of the April 15, 2026 record date.
Stockholders elected Peter Feinberg and Laurie B. Keating as Class II directors to serve until the 2029 Annual Meeting, with 26,420,287 and 27,121,501 votes for their election, respectively, and no votes against. Stockholders also approved the ratification of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 42,142,848 votes for and 1,920,218 against.
Immuneering Corporation reported updated Phase 2a results for its oral MEK inhibitor atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. As of the April 24, 2026 cutoff, median overall survival in the 320 mg intent-to-treat group of 55 patients was 17.3 months, compared with an 8.5‑month median overall survival reported for the standard of care from the MPACT trial.
Median progression-free survival in this group was 8.3 months. Among 50 response‑evaluable patients, overall response rate was 36% and disease control rate was 82%. In patients with sufficient data, 84% maintained or gained weight relative to baseline.
The combination was generally well tolerated, with Grade ≥3 anemia in 16% of patients and neutropenia in 18%, and no Grade 5 treatment‑emergent adverse events. Immuneering outlined plans to start a pivotal Phase 3 MAPKeeper 301 trial in mid‑2026 with topline data expected in mid‑2028, along with additional lung cancer and preclinical programs through 2027.
Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors targeting the MAPK pathway, led by atebimetinib (IMM-1-104). The drug is moving into MAPKeeper 301, a global Phase 3 registrational trial in first-line metastatic pancreatic cancer, planned to enroll about 510 patients.
For the three months ended March 31, 2026, Immuneering reported a net loss of $13,460,895, modestly improved from $15,046,132 a year earlier, with basic and diluted net loss per share of $0.21 versus $0.42. Operating expenses were $15,335,034, driven mainly by $10,645,222 in research and development and $4,682,495 in general and administrative costs.
Cash and cash equivalents were $47,321,566 and marketable securities totaled $151,322,802 as of March 31, 2026, supporting management’s view that current resources can fund operations into 2029. The company remains pre-revenue, focused on advancing atebimetinib through late-stage trials and progressing its broader oncology pipeline, including envometinib (IMM-6-415).